Renin-angiotensin-aldosterone system inhibitors in heart failure

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 4, 2013, Pages 459-467

  Shearer, F ^a   Lang, C C ^a   Struthers, A D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDOXATRIL; CANRENOIC ACID; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; EPLERENONE; LISINOPRIL; LOSARTAN; OMAPATRILAT; PLACEBO; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; VALSARTAN; VASOPEPTIDASE INHIBITOR;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NEPRILYSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR REMODELING;

EID: 84884500364     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.135     Document Type: Article

References (74)

1. McMurray, J.J. et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task Force for the Diagnosis and treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-1847 (2012).
2. Mizuno, Y. et al. Aldosterone production is activated in failing ventricle in humans. Circulation 103, 72-77 (2001). (Pubitemid 32050438)
3. Koitabashi, N. & Kass, D.A. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat. Rev. Cardiol. 9, 147-157 (2012).
4. Sun, Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc. Res. 81, 482-490 (2009).
5. van Vark, L.C. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158, 998 patients. Eur. Heart J. 33, 2088-2097 (2012)
6. Efects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial Study Group. N. Engl. J. Med. 316, 1429-1435 (1987).
7. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. & Dagenais, G. Efects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
8. Konstam, M.A. et al. Efects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 86, 431-438 (1992).
9. Goussev, A. et al. Efects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am. J. Physiol. 275, H626-H631 (1998). (Pubitemid 128734433)
10. Pahor, M. et al. Enalapril prevents cardiac fbrosis and arrhythmias in hypertensive rats. Hypertension 18, 148-157 (1991).
11. Elder, D.H. et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identifed to have aortic regurgitation: a large population cohort study. J. Am. Coll. Cardiol. 58, 2084-2091 (2011).
12. Elder, D.H., Lang, C.C. & Choy, A.M. Pacing-induced heart disease: understanding the pathophysiology and improving outcomes. Expert Rev. Cardiovasc. Ther. 9, 877-886 (2011).
13. Elder, D.H. et al. Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm 9, 505-510 (2012).
14. Pitt, B. et al. Efect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELItE II. Lancet 355, 1582-1587 (2000). (Pubitemid 30240502)
15. Konstam, M.A. et al.; HEAAL Investigators. Efects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374, 1840-1848 (2009).
16. Zile, M.R., Colombo, P.C., Mehra, M., Greenberg, B., Brown, S. & Konstam, M.A. Progressive improvement in cardiac performance with continuous aortic fow augmentation (aortic fow therapy) in patients hospitalized with severe heart failure: results of the Multicenter trial of the Orqis Medical Cancion System for the Enhanced treatment of Heart Failure Unresponsive to Medical therapy (MOMENtUM). J. Heart Lung Transplant. 29, 86-92 (2010).
17. Dickstein, K. & Kjekshus, J.; OPtIMAAL Steering Committee of the OPtIMAAL Study Group. Efects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPtIMAAL randomised trial. Optimal trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360, 752-760 (2002). (Pubitemid 35247704)
18. Granger, C.B. et al.; CHARM Investigators and Committees. Efects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362, 772-776 (2003). (Pubitemid 37093917)
19. McMurray, J.J. et al.; CHARM Investigators and Committees. Efects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767-771 (2003). (Pubitemid 37093916)
20. Cohn, J.N. & tognoni, G.; Valsartan Heart Failure trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001). (Pubitemid 33126822)
21. Pfefer, M.A. et al. Efect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327, 669-677 (1992).
22. Yusuf, S. et al. telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008). (Pubitemid 351522739)
23. Brilla, C.G., Zhou, G., Matsubara, L. & Weber, K.t. Collagen metabolism in cultured adult rat cardiac fbroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol. 26, 809-820 (1994). (Pubitemid 24223231)
24. MacFadyen, R.J., Barr, C.S. & Struthers, A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 35, 30-34 (1997). (Pubitemid 27374737)
25. Efectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 78, 902-907 (1996).
26. Pitt, B. et al. The efect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999). (Pubitemid 29407370)
27. Pitt, B. et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efcacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003). (Pubitemid 36384098)
28. Zannad, F. et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011).
29. Wehling, M. Efects of aldosterone and mineralocorticoid receptor blockade on intracellular electrolytes. Heart Fail. Rev. 10, 39-46 (2005). (Pubitemid 40903060)
30. Macdonald, J.E., Kennedy, N. & Struthers, A.D. Efects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90, 765-770 (2004) (Pubitemid 38813637)
31. American College of Cardiology. REMINDER trial Shows Early Eplerenone Improves Acute StEMI. CardioSource, 11 March 2013. http://www. cardiosource.org/News-Media/Publications/Cardiology-Magazine/2013/ACC-2013/ REMINDER.
32. Ouvrard-Pascaud, A. et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111, 3025-3033 (2005). (Pubitemid 40847778)
33. Shah, N.C., Pringle, S.D., Donnan, P.t. & Struthers, A.D. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J. Hypertens. 25, 2345-2351 (2007). (Pubitemid 47537930)
34. Assomull, R.G. et al. Cardiovascular magnetic resonance, fbrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1977-1985 (2006). (Pubitemid 44738448)
35. Zannad, F., Alla, F., Dousset, B., Perez, A. & Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival beneft of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102, 2700-2706 (2000).
36. Yee, K.M., Pringle, S.D. & Struthers, A.D. Circadian variation in the efects of aldosterone blockade on heart rate variability and Qt dispersion in congestive heart failure. J. Am. Coll. Cardiol. 37, 1800-1807 (2001). (Pubitemid 32499962)
37. Swedberg, K. et al.; EMPHASIS-HF Study Investigators. Eplerenone and atrial fbrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J. Am. Coll. Cardiol. 59, 1598-1603 (2012).
38. Suzuki, G. et al. Efects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106, 2967-2972 (2002). (Pubitemid 35424750)
39. Hayashi, M. et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with frst anterior acute myocardial infarction. Circulation 107, 2559-2565 (2003). (Pubitemid 36628936)
40. Udelson, J.E. et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the efect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ. Heart Fail. 3, 347-353 (2010).
41. Lund, L.H., Benson, L., Dahlström, U. & Edner, M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308, 2108-2117 (2012).
42. Cleland, J.G., tendera, M., Adamus, J., Freemantle, N., Polonski, L. & taylor, J.; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 27, 2338-2345 (2006). (Pubitemid 44453578)
43. Yusuf, S. et al.; CHARM Investigators and Committees. Efects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362, 777-781 (2003). (Pubitemid 37093918)
44. McMurray, J.J. et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur. J. Heart Fail. 10, 149-156 (2008). (Pubitemid 351227428)
45. Trial Results Center. tOPCAt trial. http://www.trialresultscenter.org/ study8849-tOPCAt.htm. Accessed 8 May 2013.
46. Nguyen, G. Renin, (pro)renin and receptor: an update. Clin. Sci. 120, 169-178 (2011).
47. Nguyen, G. The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr. Opin. Nephrol. Hypertens. 16, 129-133 (2007).
48. Moilanen, A.M. et al. (Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function. PLoS ONE 7, e41404 (2012).
49. Schroten, N.F., Gaillard, C.A., van Veldhuisen, D.J., Szymanski, M.K., Hillege, H.L. & de Boer, R.A. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail. Rev. 17, 191-201 (2012).
50. Feldman, D.L. et al. Efects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic tG(mRen-2)27 rats. Hypertension 52, 130-136 (2008).
51. Vaidyanathan, S., Jarugula, V., Dieterich, H.A., Howard, D. & Dole, W.P. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet. 47, 515-531 (2008). (Pubitemid 351969826)
52. Seed, A. et al. Neurohumoral efects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur. J. Heart Fail. 9, 1120-1127 (2007). (Pubitemid 47633316)
53. van Esch, J.H. et al. Benefcial cardiac efects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J. Hypertens. 28, 2145-2155 (2010).
54. McMurray, J.J. et al.; Aliskiren Observation of Heart Failure treatment (ALOFt) Investigators. Efects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008).
55. Solomon, S.D. et al.; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Efect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 32, 1227-1234 (2011).
56. Gheorghiade, M. et al.; AStRONAUt Investigators and Coordinators. Efect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the AStRONAUt randomized trial. JAMA 309, 1125-1135 (2013).
57. Krum, H. et al.; AtMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren trial to Minimize OutcomeS in Patients with HEart failuRE (AtMOSPHERE) study. Eur. J. Heart Fail. 13, 107-114 (2011).
58. Parving, H.H. et al. Aliskiren trial in type 2 Diabetes Using Cardio-Renal Endpoints (ALtItUDE): rationale and study design. Nephrol. Dial. Transplant. 24, 1663-1671 (2009)
59. European Society of Cardiology. Median follow-up results from the ALtItUDE study, stopped prematurely in December 2011. Press release, 26 August 2012. http://www.escardio.org/about/press/press-releases/esc12-munich/Pages/HL1- ALtItUDE.aspx.
60. Mangiafco, S., Costello-Boerrigter, L.C., Andersen, I.A., Cataliotti, A. & Burnett, J.C. Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart J. 34, 886-893c (2013).
61. Solomon, S.D. et al.; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fraction (PARAMOUNt) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380, 1387-1395 (2012).
62. Bevan, E.G. et al. Candoxatril, a neutral endopeptidase inhibitor: efcacy and tolerability in essential hypertension. J. Hypertens. 10, 607-613 (1992).
63. Lang, C.C., Motwani, J., Coutie, W.J. & Struthers, A.D. Infuence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet 338, 255 (1991).
64. McDowell, G., Coutie, W., Shaw, C., Buchanan, K.D., Struthers, A.D. & Nicholls, D.P. The efect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br. J. Clin. Pharmacol. 43, 329-332 (1997). (Pubitemid 27116076)
65. Corti, R., Burnett, J.C. Jr, Rouleau, J.L., Ruschitzka, F. & Lüscher, t.F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 104, 1856-1862 (2001). (Pubitemid 32963354)
66. Rouleau, J.L. et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356, 615-620 (2000). (Pubitemid 30627587)
67. Packer, M. et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized trial of Utility in Reducing Events (OVERtURE). Circulation 106, 920-926 (2002). (Pubitemid 34925324)
68. Kostis, J.B., Packer, M., Black, H.R., Schmieder, R., Henry, D. & Levy, E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular treatment vs. Enalapril (OCtAVE) trial. Am. J. Hypertens. 17, 103-111 (2004). (Pubitemid 38125125)
69. Fryer, R.M. et al. Efect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efcacy of enzymes associated with bradykinin-mediated angioedema. Br. J. Pharmacol. 153, 947-955 (2008). (Pubitemid 351328937)
70. Gu, J. et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 50, 401-414 (2010).
71. Ruilope, L.M., Dukat, A., Böhm, M., Lacourcière, Y., Gong, J. & Lefkowitz, M.P. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375, 1255-1266 (2010).
72. Kobalava, Z. et al. First experience with concomitant At1 and neprilysin (NEP 24.11) Inhibition with LCZ696 in patients with chronic heart failure. Circulation, 122, A19378 (2010).
73. Mearns, B.M. Heart failure: Phase II PARAMOUNt trial of LCZ696. Nat. Rev. Cardiol. 9, 612 (2012)
74. Clinicaltrials.gov. Paradigm HF trial. http://clinicaltrials.gov/ct2/ show/NCt01035255. Accessed 28 September 2012.